Active surveillance for metastatic or recurrent renal cell carcinoma
- Authors
- Park, Inkeun; Lee, Jae-Lyun; Ahn, Jin-Hee; Lee, Dae-Ho; Lee, Kyoo-Hyung; Jeong, In Gab; Song, Cheryn; Hong, Bumsik; Hong, Jun Hyuk; Ahn, Hanjong
- Issue Date
- Aug-2014
- Publisher
- SPRINGER
- Keywords
- Renal cell carcinoma; Active surveillance; Watchful waiting; Metastasis
- Citation
- JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, v.140, no.8, pp.1421 - 1428
- Journal Title
- JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Volume
- 140
- Number
- 8
- Start Page
- 1421
- End Page
- 1428
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12410
- DOI
- 10.1007/s00432-014-1680-9
- ISSN
- 0171-5216
- Abstract
- Purpose Metastatic renal cell carcinoma (mRCC) sometimes presents with an indolent course without any significant symptoms. Here, the potential impact of active surveillance (AS) on clinical outcomes in asymptomatic or minimally symptomatic mRCC patients was retrospectively evaluated. Methods mRCC patients who were followed up with deferred treatment for the purpose of AS between 2000 and 2012 were enrolled. Patient and disease characteristics, outcomes of AS and subsequent therapies, and predictive factors for rapid disease progression were analyzed. The primary endpoint was time-to-progression (TTP). Results First-line systemic therapy was deliberately deferred in 58 patients. During AS, the best overall responses were stable disease for 48 patients (83 %) and progressive disease (PD) for 10 patients (17 %), and 47 patients ultimately experienced disease progression at the time of data cutoff. With a median follow-up of 31.4 months, the median TTP was 12.4 months (95 % confidence interval 8.4-16.5) and median overall survival was not reached. After univariate and multivariate analyses for TTP, Karnofsky performance status <100 %, liver metastasis, and a time from diagnosis to AS of less than 1 year were found to be predictive factors for a shorter TTP. After PD, 30 patients received systemic treatment (14 sunitinib, 11 pazopanib, 4 immunotherapy, and 1 temsirolimus). The objective response rates were 71 % for sunitinib and 46 % for pazopanib, which were deemed comparable with historical controls. Conclusions A symptomatic or minimally symptomatic mRCC patients can be observed for a prolonged period of time without active treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12410)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.